Latanoprost / netarsudil (reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension)


  • Active Substance: Latanoprost / netarsudil
  • Name: Roclanda®
  • Therapeutic area: Open-angle glaucoma
  • Pharmaceutical company: Santen GmbH


Time table:

  • Start: 15.12.2022
  • Publication of assessment: 15.03.2023
  • End of public hearing: 05.04.2023
  • Final decision by G-BA: middle of June 2023


Comparative therapy:

  • A combination therapy of beta-blocker + prostaglandin analogue or prostamide as a free or fixed combination